First pediatric surgical quality program shows potential to measure children's outcomes

Jan 26, 2011

A first of its kind surgical quality improvement program for children has the potential to identify outcomes of children's surgical care that can be targeted for quality improvement efforts to prevent complications and save lives. The results of a study of the American College of Surgeons National Surgical Quality Improvement Program-Pediatric (ACS NSQIP Peds) phase 1 pilot were published in the January issue of the Journal of the American College of Surgeons.

A partnership of the American College of Surgeons (ACS) and the American Pediatric Surgical Association, ACS NSQIP Peds was developed based on the ACS NSQIP program, which has been shown to help hospitals prevent between 250-500 complications and save 12-36 lives per hospital per year.1 Based on the successes of ACS NSQIP, there has been great interest in a quality improvement program focused on measuring outcomes for pediatric surgery patients. The study shows the principles of ACS NSQIP can be translated to pediatric cases to help hospitals measure children's outcomes. Hospitals could then use that data to learn how to prevent complications, save lives and reduce costs.

"As components are implemented over the next several years, we will see a greater focus on measuring patient outcomes and tying reimbursement to quality of care," said Clifford Y. Ko, MD, FACS, MS, MSHS, Director, ACS Division of Research and Optimal Patient Care, and one of the study's authors. "Having robust clinical data in a nationally benchmarked, continuously updated database is an essential element to quality improvement. We now know the tools that have prevented complications and saved lives of adults can also be used for children."

In the study, outcomes for 7,287 patients who underwent a surgical procedure between October 2008 and December 2009 were collected from four participating hospitals (Yale New Haven Children's Hospital, New Haven, CT; A.I. DuPont Hospital for Children, Wilmington, DE; The Children's Hospital, Aurora, CO; and Children's of Wisconsin, Milwaukee, WI). Participants collected data for general/thoracic surgery, otolaryngology, orthopedic surgery, urology, neurosurgery and plastic surgery. The overall mortality rate was 0.3 percent and 3.9 percent of patients experienced a post-operative complication (n=287). Infection was the most common complication, and rates varied by specialty and procedure. Variability in the rate of complications indicates that there are opportunities to identify what rates are above and below the hospital's expected rate, and for hospitals with higher than expected rates of complication to learn from those centers with low rates in order to improve quality of care.

The program is currently in the pilot stage, and future developments will focus on risk-adjusting data to account for the health of the patient prior to the operation, and targeting specific procedures so that hospitals can focus quality improvement efforts on procedures with higher rates of complications. The program is now in phase 2 of development at 29 hospitals around the country.

Explore further: New drug sales help boost Novartis Q1 profit (Update)

More information: Hall, BL et al. "Does Surgical Quality Improve in the American College of Surgeons National Surgical Quality Improvement Program." Ann Surg. 2009 Sep; 250(3):363-76.

add to favorites email to friend print save as pdf

Related Stories

Top-rated hospitals don't always have superior outcomes

Jan 26, 2010

New research published in the January issue of the Journal of the American College of Surgeons finds that while popular hospital rating systems can help identify high-quality hospitals for cardiovascular operations, patien ...

Recommended for you

Amgen misses 1Q views as higher costs cut profit

Apr 22, 2014

Despite higher sales, biotech drugmaker Amgen's first-quarter profit fell 25 percent as production and research costs rose sharply, while the year-ago quarter enjoyed a tax benefit. The company badly missed ...

Valeant, Ackman make $45.6B Allergan bid

Apr 22, 2014

Valeant Pharmaceuticals and activist investor Bill Ackman have unveiled details of their offer to buy Botox maker Allergan, proposing a cash-and-stock deal that could be worth about $45.6 billion.

User comments : 0

More news stories

Genetic code of the deadly tsetse fly unraveled

Mining the genome of the disease-transmitting tsetse fly, researchers have revealed the genetic adaptions that allow it to have such unique biology and transmit disease to both humans and animals.